DLGAP2

DLGAP2 is a postsynaptic density scaffold protein that maintains the molecular composition and physiological function of excitatory synapses (PMID:25071926). It is a component of the PSD-95/SAP90-associated scaffold complex (PMID:33347690, PMID:10854099) and is required to sustain levels of synaptic proteins including PSD-95 and CaMKIIβ; its loss reduces dendritic spine density, diminishes miniature EPSC amplitude, and produces ultrastructural defects of the postsynaptic density (PMID:25071926, PMID:39631506). Mechanistically, DLGAP2 directly interacts with Intersectin-1 (ITSN1) at the postsynaptic density, and DLGAP2 deficiency triggers ubiquitin-mediated proteasomal degradation of ITSN1, disrupting synaptic organization and producing autism-like behaviors (PMID:41673270). Both loss and gain of DLGAP2 are detrimental: knockout impairs associative learning, olfactory transmission, and reaction times (PMID:33347690, PMID:39631506), while hippocampal overexpression impairs synaptic plasticity and worsens memory deficits in an Alzheimer's disease model [PMID:bio_10.1101_2025.05.13.653830]. DLGAP2 expression is controlled by allele-specific DNA methylation at a defined regulatory region, linking epigenetic regulation of the gene to behavioral phenotypes including alcohol reward processing (PMID:31745236).

1. 2000 Medium

   Established the molecular identity of human DLGAP2, defining its genomic structure and revealing alternative splicing that generates distinct brain and testis transcripts of the PSD-95/SAP90-associated protein.

   Evidence Positional cloning, cDNA library screening, and sequence comparison with rat Dlgap2

   PMID:10854099

   Open questions at the time

   • No functional assay of the protein product
   • Tissue-specific roles of the splice variants not tested
2. 2009 Low

   Linked DLGAP2 to stress-related behavior by showing that hippocampal Dlgap2 methylation and expression track PTSD-like phenotypes, raising the question of epigenetic control of the gene.

   Evidence Methylation screening and qRT-PCR in a rat PTSD model, correlated with behavior

   PMID:19793403

   Open questions at the time

   • Correlative only — methylation was not manipulated to establish causality
   • No demonstration that altered DLGAP2 drives the behavioral phenotype
3. 2014 High

   Demonstrated that DLGAP2 is required to maintain synaptic protein composition and excitatory transmission, moving it from a sequence entity to a functional postsynaptic scaffold.

   Evidence Dlgap2 knockout mice analyzed by synaptosomal fractionation, Golgi-Cox staining, patch-clamp, and electron microscopy

   PMID:25071926

   Open questions at the time

   • Direct binding partners within the PSD not biochemically resolved here
   • Mechanism by which DLGAP2 stabilizes synaptic proteins not defined
4. 2014 Medium

   Showed that human regulatory variants alter DLGAP2 dosage, establishing that expression level — not just loss — is functionally consequential.

   Evidence Luciferase reporter assay of schizophrenia-associated promoter variants

   PMID:24416398

   Open questions at the time

   • In vitro reporter context only
   • Effect on endogenous DLGAP2 in neurons not shown
5. 2017 Medium

   Placed DLGAP2 within the PSD-95 protein complex as a regulator of excitatory synapse signaling underlying cognition.

   Evidence Touchscreen cognitive testing of Dlgap2 loss-of-function mice

   PMID:33347690

   Open questions at the time

   • Complex membership inferred from genetic context rather than reconstitution
   • Causal molecular link between PSD-95 association and the cognitive deficit not established
6. 2019 Medium

   Connected allele-specific DNA methylation to DLGAP2 expression and reward behavior, establishing an epigenetic regulatory layer over the gene.

   Evidence Epigenome-wide association of human brain methylation, in vitro methylation-reporter assay, and alcohol consumption in Dlgap2 KO mice

   PMID:31745236

   Open questions at the time

   • Direct causal chain from methylation to behavior in vivo not closed
   • Cell types driving the methylation effect unresolved
7. 2024 Medium

   Confirmed that DLGAP2 sustains specific synaptic proteins by showing PSD-95 and CaMKIIβ levels fall in DLGAP2-null olfactory bulb, generalizing the scaffold-maintenance role beyond cortex.

   Evidence Immunoblotting, c-fos immunostaining, and olfactory behavior in Dlgap2 KO mice

   PMID:39631506

   Open questions at the time

   • Whether protein loss is due to reduced synthesis or accelerated degradation not determined
   • Single-lab measurement
8. 2025 Medium

   Demonstrated that elevated DLGAP2 is itself pathogenic, showing gain-of-function impairs plasticity and worsens memory in an AD model and defining a bidirectional dosage sensitivity.

   Evidence Viral hippocampal overexpression with electrophysiology and behavioral testing in 5XFAD mice (preprint)

   PMID:bio_10.1101_2025.05.13.653830

   Open questions at the time

   • Preprint, single lab
   • Molecular basis of the overexpression toxicity not defined
9. 2026 Medium

   Identified a direct DLGAP2–ITSN1 axis, providing the first molecular mechanism whereby DLGAP2 stabilizes a partner by preventing its ubiquitin-mediated degradation.

   Evidence PSD proteomics after Dlgap2 knockdown, co-immunoprecipitation, ubiquitin-degradation assay, and mouse behavior

   PMID:41673270

   Open questions at the time

   • No reciprocal validation or mutagenesis of the interaction interface reported
   • Whether the same mechanism stabilizes PSD-95 and CaMKIIβ untested
   • Identity of the responsible E3 ligase unknown

• How DLGAP2 mechanistically prevents degradation of its partner proteins and the structural basis of its scaffolding within the PSD remain undefined.
• No structural model of DLGAP2 or its complexes
• E3 ligase and degradation machinery acting on ITSN1 not identified
• Mechanism linking DLGAP2 dosage bidirectionally to plasticity unresolved